The estimated Net Worth of Curtis Ruegg is at least $205 Tisíc dollars as of 13 June 2016. Curtis Ruegg owns over 1,000 units of Revance Therapeutics Inc stock worth over $164,132 and over the last 11 years Curtis sold RVNC stock worth over $41,100.
Curtis has made over 27 trades of the Revance Therapeutics Inc stock since 2014, according to the Form 4 filled with the SEC. Most recently Curtis exercised 1,000 units of RVNC stock worth $8,700 on 13 June 2016.
The largest trade Curtis's ever made was exercising 3,000 units of Revance Therapeutics Inc stock on 17 August 2015 worth over $26,100. On average, Curtis trades about 1,029 units every 18 days since 2014. As of 13 June 2016 Curtis still owns at least 24,944 units of Revance Therapeutics Inc stock.
You can see the complete history of Curtis Ruegg stock trades at the bottom of the page.
Curtis's mailing address filed with the SEC is C/O REVANCE THERAPEUTICS, INC., 7555 GATEWAY BOULEVARD, NEWARK, CA, 94560.
Over the last 11 years, insiders at Revance Therapeutics Inc have traded over $29,070,398 worth of Revance Therapeutics Inc stock and bought 136,530 units worth $2,014,047 . The most active insiders traders include Vlad Coric, Julian S Gangolli a Angus C. Russell. On average, Revance Therapeutics Inc executives and independent directors trade stock every 31 days with the average trade being worth of $83,132. The most recent stock trade was executed by Erica Jordan on 16 April 2024, trading 2,392 units of RVNC stock currently worth $9,090.
revance therapeutics, inc. is a specialty biopharmaceutical company focused on the development, manufacturing and commercialization of novel botulinum toxin products for multiple aesthetic and therapeutic indications. the company is leveraging its proprietary portfolio of botulinum toxin compounds combined with its patented transmts® peptide delivery system to address unmet needs in the $3 billion neurotoxin market. revance's proprietary transmts technology enables delivery of botulinum toxin a through two novel dose formulations, a needle-free topical form and an injectable form that may localize the drug to the site of injection resulting in a more targeted and potentially longer lasting delivery. revance is currently pursuing clinical development for two product candidates, topical rt001 and injectable rt002, in a broad spectrum of aesthetic and therapeutic indications. rt001 is a topical gel, which has the potential to be the first commercially available non-injectable dose form
Revance Therapeutics Inc executives and other stock owners filed with the SEC include: